ArticlePigment cell & melanoma research2011
In vitro studies of dasatinib, its targets and predictors of sensitivity.
Article in Pigment cell & melanoma research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Trial
- Clinical Significance of PDCD4 in Melanoma by Subcellular Expression and in Tumor-Associated Immune Cells.Cancers · 2021Article
- Post-treatment de-phosphorylation of p53 correlates with dasatinib responsiveness in malignant melanoma.BMC cell biology · 2018Article
- Design, Synthesis, and Evaluation of Dasatinib-Amino Acid and Dasatinib-Fatty Acid Conjugates as Protein Tyrosine Kinase Inhibitors.ChemMedChem · 2017Article
- SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma.Annals of surgical oncology · 2014Article
- Predictive biomarkers for dasatinib treatment in melanoma.Oncoscience · 2014Article
- Advances in the systemic treatment of metastatic melanoma.Oncology (Williston Park, N.Y.) · 2013Review
- Driver mutations in melanoma: lessons learned from bench-to-bedside studies.Current oncology reports · 2012Review
- Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma.British journal of cancer · 2012Article
- Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.Neoplasia (New York, N.Y.) · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.